inspection – Page 71

Electronic signatures misused during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Electronic Signature Misuse Throughout the Validation Lifecycle In pharmaceutical manufacturing and quality control, the implementation of electronic signatures holds significant potential for operational efficiency and compliance. However, misuse of…

Requalification overdue during site expansion – risk-based validation alignment

Managing Requalification During Site Expansion: A Risk-Based Validation Approach In the dynamic landscape of pharmaceutical manufacturing, the process of site expansion presents unique challenges, particularly when it comes to maintaining…

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – CAPA and revalidation strategy

Addressing Uncontrolled Hybrid Paper-Electronic Workflows in Validation Lifecycle In today’s pharmaceutical landscape, hybrid paper-electronic workflows present significant challenges, particularly in maintaining compliance during the validation lifecycle. As organizations strive for…

Inadequate worst-case selection during site expansion – risk-based validation alignment

“`html Addressing Inadequate Worst-Case Selection in Site Expansion: A Practical Playbook In the rapidly evolving landscape of pharmaceutical manufacturing, site expansions pose significant challenges, notably in ensuring appropriate validations are…

System access controls weak during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Weaknesses in System Access Controls During the Validation Lifecycle In the fast-paced pharmaceutical environment, compliance with 21 CFR Part 11 is critical. However, weaknesses in system access controls can…

Validation gaps identified during system upgrades – regulatory deficiency risk

Addressing Validation Gaps Identified During System Upgrades to Mitigate Regulatory Deficiency Risks Pharmaceutical manufacturing is fraught with challenges, particularly when it comes to validation and regulatory compliance during system upgrades.…

GLP study documentation gaps during internal audit – alignment with OECD principles

“`html Addressing GLP Study Documentation Gaps During Internal Audits in Accordance with OECD Principles Internal audits are crucial for identifying compliance gaps related to Good Laboratory Practices (GLP) and ensuring…

Record retention failures during system operation – 21 CFR Part 11 compliance gaps

A Comprehensive Playbook for Addressing Record Retention Failures in Pharmaceutical Systems Record retention failures pose significant challenges during system operation, especially in relation to compliance with 21 CFR Part 11.…

Incomplete validation lifecycle during system upgrades – CAPA and revalidation strategy

“`html Managing Incomplete Validation Lifecycle During System Upgrades: A Comprehensive Playbook In the dynamic environment of pharmaceutical manufacturing, incomplete validation lifecycles during system upgrades can lead to compliance failures, resulting…

System access controls weak during system upgrade – preventing repeat Part 11 findings

Addressing Weak System Access Controls During Upgrades to Prevent Part 11 Findings The pharmaceutical industry is continuously advancing, particularly with the integration of electronic recordkeeping systems. However, these upgrades can…

Validation gaps identified during lifecycle management – inspection evidence expectations

Addressing Validation Issues in Pharmaceutical Lifecycle Management for Enhanced Inspection Readiness Validation is a critical component of effective pharmaceutical manufacturing, ensuring that processes and products meet regulatory standards and quality…

Electronic signatures misused during system upgrade – risk-based ERES remediation

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system…